Table 1 Clinicopathological characteristics of the 74 patients with HGSC
Mean or number | Range or percentage | |
|---|---|---|
Age at diagnosis (years) | 53.41 ± 9.29 | 34–76 |
Menopausal status | ||
Pre-menopausal | 23 | 31.1% |
Post-menopausal | 51 | 68.9% |
Family history of cancer | ||
Yes | 6 | 8.1% |
No | 68 | 91.9% |
Preoperative CA125 levels (IU/ml) | 2005.42 ± 3137.71 | 15–17,980 |
FIGO stage | ||
Stage I | 10 | 13.5% |
Stage II | 6 | 8.1% |
Stage III | 52 | 70.3% |
Stage IV | 6 | 8.1% |
Lymphatic metastasis | ||
Yes | 28 | 37.8% |
No | 46 | 62.2% |
Cytoreductive surgery | ||
Residual tumor ≤ 1 cm | 53 | 71.6% |
Residual tumor > 1 cm | 22 | 29.7% |
Current status | ||
NED | 25 | 33.8% |
AWD | 19 | 25.7% |
DOD | 30 | 40.5% |